Point72 Hong Kong’s Carisma Therapeutics CARM Stock Holding History

Point72 Hong Kong’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4	Closed	–	–	2003
2021 Q2	$0	Buy	+4	New	+$255	﹤0.01%	1949

Other funds holding CARM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Point72 Hong Kong's CARM Position: Q3 2021 in Review

Point72 Hong Kong sold out of Carisma Therapeutics (CARM) in Q3 2021, closing a stake of 4 shares.

Point72 Hong Kong first reported a position in CARM in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 103 funds tracked by Wall St. Rank hold CARM as of Q3 2021.

Point72 Hong Kong reported no remaining Carisma Therapeutics position as of Q3 2021 after selling out during the quarter.
Point72 Hong Kong sold 4 Carisma Therapeutics shares in Q3 2021.
Point72 Hong Kong first reported a position in Carisma Therapeutics in Q2 2021 and held it in 1 quarter.
Point72 Hong Kong's Carisma Therapeutics position peaked at $0 in Q2 2021.
103 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2021.

Based on Point72 Hong Kong's 13F filing for Q3 2021, filed 15 Nov 2021.